About Contact Us Careers
Sign In

Wilson Disease Drugs Market Size & Share, by Indication (Hepatic, Neurological, Ophthalmic, Psychiatric); Drug Type (Chelating Agents, Zinc, Tetrathiomolybdate); End-user (Hospitals, Pharmacies, Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2863
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Companies Dominating the Wilson Disease Drugs Landscape

top-features-companies
    • Merck & Co., Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • Alexion Pharmaceuticals, Inc.
    • Nobelpharma Co., Ltd.
    • Kodmon Holdings, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Tsumura & Co.
    • VHB Medi Sciences Limited
    • Pfizer Inc.
    • Lupin Limited
    • Vivet Therapeutics
    • NAVINTA LLC
Browse Key Market Insights with Data Illustration:

In the News

  • Alexion Pharmaceuticals, Inc. made an announcement regarding the acquisition of LogicBio Therapeutic, Inc. The acquisition took place to accelerate the growth of Alexion Pharmaceuticals in developing genomic medicines using the unique technology of LogicBio.

  • Kadmon Holdings, Inc. announced that its generic Trientine Hydrochloride Capsules USP, 250 mg, which is a chelating agent used for the treatment of Wilson’s disease in patients who are intolerant of penicillamine, has been approved by the U.S. Food and Drug Administration (FDA).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2863
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of Wilson’s disease in the young population and increasing health spending across the globe are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

Lack of awareness in low-income countries and requirement for higher initial investments are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Nobelpharma Co., Ltd., Kodmon Holdings, Inc., Teva Pharmaceutical Industries Ltd., Tsumura & Co., VHB Medi Sciences Limited, Pfizer Inc., Lupin Limited, Vivet Therapeutics, NAVINTA LLC, and others.

The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by indication, drug type, end-user, and by region.

The neurological segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying